Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: Leflunomide in Previously Treated Metastatic Triple Negative Cancers [Phase 1, Phase 2]
Clinical trial update shows completion of a Phase 1/2 study evaluating leflunomide in previously treated metastatic triple-negative breast c…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer [NA]
This ClinicalTrials.gov entry describes an ongoing study evaluating brain MRI screening in patients with breast cancer, including HER2-posit…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment
This clinical trial aims to establish an ex vivo collection of triple-negative breast cancers to evaluate innovative therapies and identify …
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer [NA]
This entry describes a clinical trial focused on developing patient-derived xenografts from surgical tumor samples in patients with triple-n…
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases [Phase 1, Phase 2]
A Phase 1/2 trial evaluating Bintrafusp alfa in combination with Pimasertib for brain metastases has been terminated, with results posted in…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) [Phase 3]
Phase 3 TROPION-Breast03 trial evaluating datopotamab deruxtecan (Dato-DXd) with or without durvalumab versus investigator's choice in Stage…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Access to Genetic Testing in Underserved Patients With Cancer [NA]
This entry reports on a clinical trial investigating access to genetic testing for cancer patients in underserved populations, with recruitm…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs [Phase 1]
Phase 1 dose randomization study evaluating Bulumtatug Fuvedotin in triple-negative breast cancer patients previously treated with antibody-…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging [NA]
A clinical trial evaluating early detection of metastatic recurrence in Stage II/III triple-negative breast cancer using liquid biopsy and i…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors [Phase 2]
A Phase 2 clinical trial of disitamab vedotin in combination with other anticancer drugs for solid tumors is currently recruiting, including…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. [Phase 2]
Phase 2 trial by the SOLTI Breast Cancer Research Group to predict sensitivity to Olaparib in patients with unresectable locally advanced or…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer [Phase 3]
Phase 3 clinical trial evaluating AK112 plus nab-paclitaxel versus placebo plus nab-paclitaxel as first-line treatment for inoperable locall…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer [Phase 2]
Phase 2 clinical trial comparing Tobemstomig plus nab-paclitaxel versus pembrolizumab plus nab-paclitaxel in previously untreated PD-L1-posi…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Cardiac Outcomes With Near-Complete Estrogen Deprivation [NA]
This entry reports an ongoing Duke University clinical trial evaluating cardiac outcomes in patients with breast cancer undergoing near-comp…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer [Phase 2]
Phase 2 study of AK117/AK112 for metastatic and locally advanced triple-negative breast cancer is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID [Phase 1]
Phase 1 clinical trial update of RNA-immunotherapy IVAC_W_bre1_uID and IVAC_M_uID in triple-negative breast cancer, with the study status no…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer [Phase 2]
This Clinical Trials update describes the I-SPY TRIAL, a Phase 2 neoadjuvant breast cancer study using personalized adaptive agents; recruit…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy [Phase 2]
A Phase 2 exploratory clinical study is evaluating camrelizumab plus risedronate and chemotherapy for triple-negative breast cancer, focusin…
-
CLINICAL_TRIALS withdrawal · 2026-03-13Clinical Trial Update: Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer
The clinical trial assessing PD-L1 imaging with 89Zr-atezolizumab in metastatic triple-negative breast cancer has been terminated.
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors [Phase 1]
Phase 1 study evaluating NKT5097 in adults with advanced or metastatic solid tumors, including various breast cancer subtypes and gynecologi…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer [Phase 2]
This document describes a Phase 2 trial evaluating serplulimab in combination with SHR-A1811 as neoadjuvant therapy for triple-negative brea…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution
This clinical trial update describes a feasibility study using serial image-guided biopsies across multiple sites to study how breast cancer…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This clinical trial update describes the use of a live tumor diagnostic platform to evaluate immune checkpoint inhibitor responses across mu…
-
CLINICAL_TRIALS withdrawal · 2026-03-11Clinical Trial Update: A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer [Phase 1]
A Phase 1 study evaluating intratumoral influenza vaccine administration in patients with breast cancer has been withdrawn.
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) [Phase 1, Phase 2]
This trial update covers a dose-finding Phase 1 study of sarilumab plus capecitabine in HER2-negative metastatic breast cancer and a Phase 2…